Typhim Vi Injection, Solution
NDC Package 49281-790-20

11-digit billing NDC: 49281079020 · Billing unit: ML · 10 ML per package

Package Information

Typhim Vi (salmonella typhi ty2 vi polysaccharide antigen) injection is typhim Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. This formulation utilizes a injection, solution delivery system. Marketed by Sanofi Vaccines Us Inc., this product is identified by NDC 49281-790 and is authorized under FDA application BLA103936.

Identification & Billing

NDC Package Code
49281-790-20
Package Description
1 VIAL, MULTI-DOSE in 1 PACKAGE / 10 mL in 1 VIAL, MULTI-DOSE (49281-790-38)
Product Code
11-Digit Billing Format
49281079020
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
10 ML
RxNorm Crosswalk
  • RxCUI: 1486496 - Typhim Vi 0.5 ML Prefilled Syringe
  • RxCUI: 1486496 - 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI]
  • RxCUI: 1486496 - 0.5 ML Typhim VI 0.05 MG/ML Prefilled Syringe
  • RxCUI: 1486496 - Typhim VI 25 MCG per 0.5 ML Prefilled Syringe
  • RxCUI: 807222 - typhoid Vi polysaccharide vaccine (generic for Typhim Vi) Injectable Solution

Clinical Specifications

Proprietary Name
Typhim Vi
Non-Proprietary Name
Salmonella Typhi Ty2 Vi Polysaccharide Antigen
Substance Name
Salmonella Typhi Ty2 Vi Polysaccharide Antigen
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intramuscular - Administration within a muscle.
Usage Information
Typhim Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. Immunization with Typhim Vi vaccine should occur at least two weeks prior to expected exposure to S typhi. Typhim Vi vaccine is not indicated for routine immunization of individuals in the United States (US). (14)Selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with S typhi. (14)Typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as Africa, Asia, and Central and South America where there is a recognized risk of exposure to S typhi. Current CDC advisories should be consulted with regard to specific locales. Vaccination is particularly recommended for travelers who will have prolonged exposure to potentially contaminated food and water. However, even travelers who have been vaccinated should use caution in selecting food and water. (15)There is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disaster or in persons attending rural summer camps. (14)An optimal reimmunization schedule has not been established. Reimmunization every two years under conditions of repeated or continued exposure to the S typhi organism is recommended at this time. For recommended primary immunization and reimmunization see DOSAGE AND ADMINISTRATION section.Typhim Vi vaccine should not be used to treat a patient with typhoid fever or a chronic typhoid carrier.

Regulatory & Marketing

Labeler Name
Sanofi Vaccines Us Inc.
Product Type
Vaccine
FDA Application #
BLA103936
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
11-28-1994
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (49281-790). Click a package code to view its specific billing and regulatory data.

1 SYRINGE in 1 PACKAGE / .5 mL in 1 SYRINGE (49281-790-88)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49281-790-20 identifies a specific commercial package of 1 vial, multi-dose in 1 package / 10 ml in 1 vial, multi-dose (49281-790-38) of Typhim Vi, a vaccine label labeled by Sanofi Vaccines Us Inc.. This product is billed per "ML" milliliter and contains an estimated amount of 10 billable units per package. This injection, solution is formulated for intramuscular use and contains salmonella typhi ty2 vi polysaccharide antigen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi Vaccines Us Inc. on November 28, 1994. The current certification is valid through December 31, 2027.

How is this Sanofi Vaccines Us Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49281079020. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49281-790-20
11-Digit CMS (5-4-2)
49281-0790-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.